AZNAstraZenecaSigning up patients
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Non-small Cell Lung Cancer (NSCLC)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 400 (planned)
- Started
- Oct 31, 2025
- Main results expected
- Jan 29, 2029
- Fully finished
- Jan 29, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free survival (PFS)
Measured over: Approximately 2.5 years
Overall survival (OS)
Measured over: Approximately 3.5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07291037 · record last updated 2026-10-13 · checked 2026-11-09 15:47 UTC